CLINICAL TRIALS PROFILE FOR FENOLDOPAM MESYLATE
✉ Email this page to a colleague
All Clinical Trials for FENOLDOPAM MESYLATE
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00286403 ↗ | Vasodilators and Anti-Oxidant Therapy in Early ATN | Withdrawn | Dialysis Clinic, Inc. | Phase 2/Phase 3 | 2008-08-01 | Patients developing kidney failure after open heart surgery experience an abrupt decrease in blood flow to the kidney. The investigators hypothesize that administration of fenoldopam mesylate (a drug that increases blood flow to the kidney) to patients early in the course of their disease could reduce progression to dialysis-dependent acute renal failure. The investigators also hypothesize that restoring blood flow could induce additional injury to the kidney through the release of reactive oxygen species. Therefore, patients in this protocol will be randomized to receive a fenoldopam or the anti-oxidant MESNA. The investigators hypothesize that combination treatment with Fenoldopam and MESNA will decrease the incidence of death or dialysis at 21 days in patients with early post-operative acute renal failure. |
| NCT00286403 ↗ | Vasodilators and Anti-Oxidant Therapy in Early ATN | Withdrawn | Southeast Renal Research Institute | Phase 2/Phase 3 | 2008-08-01 | Patients developing kidney failure after open heart surgery experience an abrupt decrease in blood flow to the kidney. The investigators hypothesize that administration of fenoldopam mesylate (a drug that increases blood flow to the kidney) to patients early in the course of their disease could reduce progression to dialysis-dependent acute renal failure. The investigators also hypothesize that restoring blood flow could induce additional injury to the kidney through the release of reactive oxygen species. Therefore, patients in this protocol will be randomized to receive a fenoldopam or the anti-oxidant MESNA. The investigators hypothesize that combination treatment with Fenoldopam and MESNA will decrease the incidence of death or dialysis at 21 days in patients with early post-operative acute renal failure. |
| NCT01073189 ↗ | Intra-Renal Therapy of Diuretic Unresponsive Acute Kidney Injury | Withdrawn | Southeast Renal Research Institute | Phase 4 | 2010-04-01 | Randomized prospective trial of patients with diuretic unresponsive acute kidney injury where patients will receive standard supportive therapy with diuretics versus intra-renal delivery of the vasodilator fenoldopam mesylate. Patients with rising creatinine who fail to respond to bolus diuretics will be treated with a prolonged course of diuretics or undergo placement of a catheter within the renal arteries that allows for infusion of fenoldopam mesylate. The rational is that early delivery of a high dose vasodilator may reverse the decline of renal function in patients with severe acute kidney injury. |
| NCT01690832 ↗ | Fenoldopam for Prevention of Acute Kidney Injury | Unknown status | University of Roma La Sapienza | Phase 4 | 2012-09-01 | Patients with acute coronary syndromes (ACS) are at increased risk for acute kidney injury (AKI) when they undergo urgent/emergency coronary angiography. The optimal medical treatment for preventing the occurrence of contrast induced - acute kidney injury is still controversial. Fenoldopam mesylate is a dopamine A1 receptor agonist that augments renal plasma flow that has reduced the risk of radiocontrast dye nephropathy in some (but not all) preliminary studies. Neutrophil gelatinase-associated lipocalin (NGAL) is a new biomarker predictive for AKI already shown to be useful for earlier diagnosis of contrast induced nephropathy. The primary objective of this study is to to test the hypothesis that fenoldopam, in addition to standard treatment, reduce the occurrence of contrast induced - acute kidney injury in patients with acute coronary syndrome (ACS) undergoing urgent/emergency coronary angiography and/or percutaneous coronary intervention. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for FENOLDOPAM MESYLATE
Condition Name
Clinical Trial Locations for FENOLDOPAM MESYLATE
Trials by Country
Clinical Trial Progress for FENOLDOPAM MESYLATE
Clinical Trial Phase
Clinical Trial Sponsors for FENOLDOPAM MESYLATE
Sponsor Name
